Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.58 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.50 |
| ▸ | NAMPT | P43490 | 2/20 | 0.49 |
| ▸ | CA1 | P00915 | 2/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
| ▸ | FFAR1 | O14842 | 6/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.48 |
| ▸ | SDCBP | O00560 | 1/20 | 0.47 |
| ▸ | SDC2 | P34741 | 1/20 | 0.47 |
| ▸ | PPARG | P37231 | 1/20 | 0.47 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA7 | P43166 | 1/20 | 0.46 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.46 |
| ▸ | RXRA | P19793 | 1/20 | 0.46 |
| ▸ | RXRB | P28702 | 1/20 | 0.46 |
| ▸ | RXRG | P48443 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22527028 | 0.91 | CA1 (0.50) | EPHX2NR1H4L3MBTL1HDAC1NAMPT | |
| SCHEMBL22526832 | 0.90 | CA1 (0.49) | EPHX2NR1H4L3MBTL1HDAC1NAMPT | |
| SCHEMBL22527035 | 0.89 | S1PR1 (0.51) | EPHX2NR1H4L3MBTL1HDAC1NAMPT | |
| SCHEMBL24542517 | 0.88 | L3MBTL1 (0.51) | EPHX2NR1H4L3MBTL1HDAC1NAMPT | |
| SCHEMBL4498509 | 0.88 | CA2 (0.57) | EPHX2NR1H4NAMPTCA1CA2 | |
| SCHEMBL3180689 | 0.87 | L3MBTL1 (0.61) | L3MBTL1HDAC1NAMPTCA1CA2 | |
| SCHEMBL8143923 | 0.87 | CA1 (0.51) | EPHX2NR1H4L3MBTL1HDAC1NAMPT | |
| SCHEMBL5931039 | 0.87 | HTT (0.59) | L3MBTL1HDAC1NAMPTCA1CA2 | |
| SCHEMBL8130509 | 0.87 | L3MBTL1 (0.50) | EPHX2NR1H4L3MBTL1HDAC1NAMPT | |
| SCHEMBL5729298 | 0.86 | GLS (0.54) | EPHX2NR1H4HDAC1CA1FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106834081-A | A kind of vertical purple potato pears compound fruit vinegar fermentation tank control system and its method of work | 徐州工程学院 | 2017-06-13 | — | — | CN | claimed |
| EP-3305900-A1 | ENZYMATIC ENCODING METHODS FOR EFFICIENT SYNTHESIS OF LARGE LIBRARIES | Nuevolution A/S (DK) | 2018-04-11 | — | — | EP | disclosed |
| CN-106834081-A | A kind of vertical purple potato pears compound fruit vinegar fermentation tank control system and its method of work | 徐州工程学院 | 2017-06-13 | — | — | CN | disclosed |
| EP-1470102-B1 | SUBSTITUTED METHYLENE AMIDE DERIVATIVES AS MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPS) | MERCK SERONO SA (CH) | 2011-05-25 | — | — | EP | disclosed |
| US-7592477-B2 | Substituted methylene amide derivatives as modulators of protein tyrosine phosphatases (PTPs) | LABORATOIRES SERONO SA (CH) | 2009-09-22 | — | — | US | disclosed |
| EP-1401809-B1 | TRYPTASE INHIBITORS | ALTANA PHARMA AG (DE) | 2006-12-20 | — | — | EP | disclosed |
| US-20050256171-A1 | Pyrrolidine derivatives as tryptase inhibitors | ALTANA PHARMA A G (DE) | 2005-11-17 | — | — | US | disclosed |
| US-6962941-B2 | Tryptase inhibitors | ALTANA PHARMA AG (DE) | 2005-11-08 | — | — | US | disclosed |
| US-6960588-B1 | Tryptase inhibitors | ALTANA PHARMA AG (DE) | 2005-11-01 | — | — | US | disclosed |
| US-6924305-B2 | Diazocine derivatives and their use as tryptase inhibitors | ALTANA PHARMA AG (DE) | 2005-08-02 | — | — | US | disclosed |
| EP-0483667-B1 | Cyclic imino derivatives, process for their preparation and drugs containing them | THOMAE GMBH DR K (DE) | 1998-02-04 | — | — | EP | disclosed |
| US-5616620-A | HYPOTENSIVE AGENTS | KARL THOMAE GMBH (DE) | 1997-04-01 | — | — | US | disclosed |
| EP-0386839-B1 | Tetrahydroquinoline derivatives useful for neurodegenerative disorders | MERCK SHARP & DOHME (GB) | 1997-01-15 | — | — | EP | disclosed |
| US-5591769-A | PYRROLIDINE DERIVATIVES; ANTICOAGULANTS | KARL THOMAE GMBH (DE) | 1997-01-07 | — | — | US | disclosed |
| US-5541343-A | ANTIAGGLOMERANTS FOR CELLS OR ANTICOAGULANTS | KARL THOMAE GMBH (DE) | 1996-07-30 | — | — | US | disclosed |
| EP-0680469-A1 | AMINOACID DERIVATES, MEDICAMENTS CONTAINING THESE COMPOUNDS AND PROCESS FOR PREPARING THE SAME | Dr. Karl Thomae GmbH (DE) | 1995-11-08 | — | — | EP | disclosed |
| WO-1994017035-A1 | AMINOACID DERIVATES, MEDICAMENTS CONTAINING THESE COMPOUNDS AND PROCESS FOR PREPARING THE SAME | DR. KARL THOMAE GMBH (DE) | 1994-08-04 | — | — | WO | disclosed |
| US-5231102-A | Tetrahydroquinoline derivatives useful for neurodegenerative disorders | MERCK SHARP & DOHME, LTD. (GB) | 1993-07-27 | — | — | US | disclosed |
| EP-0483667-A2 | Cyclic imino derivatives, process for their preparation and drugs containing them | Dr. Karl Thomae GmbH (DE) | 1992-05-06 | — | — | EP | disclosed |
| EP-0386839-A2 | Tetrahydroquinoline derivatives useful for neurodegenerative disorders | MERCK SHARP & DOHME LTD. (GB) | 1990-09-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050256171-A1 | Pyrrolidine derivatives as tryptase inhibitors | TPSAB1, TPSB2, TPSD1 | EPHX2 2345/4885NR1H4 4137/4885L3MBTL1 4162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.